403 related articles for article (PubMed ID: 18814047)
1. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
2. Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk.
Nan H; Qureshi AA; Hunter DJ; Han J
Br J Dermatol; 2008 Aug; 159(2):314-21. PubMed ID: 18510673
[TBL] [Abstract][Full Text] [Related]
3. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
4. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
5. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
6. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.
Wilkening S; Hemminki K; Rudnai P; Gurzau E; Koppova K; Försti A; Kumar R
Br J Dermatol; 2007 Aug; 157(2):375-7. PubMed ID: 17553029
[TBL] [Abstract][Full Text] [Related]
7. Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma.
Zhang JN; Yi SH; Zhang XH; Liu XY; Mao Q; Li SQ; Xiong WH; Qiu YM; Chen T; Ge JW
Genet Mol Res; 2012 Oct; 11(4):3618-28. PubMed ID: 23096687
[TBL] [Abstract][Full Text] [Related]
8. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
9. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
10. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
Wan Y; Wu W; Yin Z; Guan P; Zhou B
BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
[TBL] [Abstract][Full Text] [Related]
11. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
[TBL] [Abstract][Full Text] [Related]
12. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.
Horikawa Y; Nadaoka J; Saito M; Kumazawa T; Inoue T; Yuasa T; Tsuchiya N; Nishiyama H; Ogawa O; Habuchi T
Oncol Rep; 2008 Jul; 20(1):49-55. PubMed ID: 18575717
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness.
Capasso M; Ayala F; Avvisati RA; Russo R; Gambale A; Mozzillo N; Ascierto PA; Iolascon A
J Hum Genet; 2010 Aug; 55(8):518-24. PubMed ID: 20535124
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma.
Cotignola J; Chou JF; Roy P; Mitra N; Busam K; Halpern AC; Orlow I
J Invest Dermatol; 2012 May; 132(5):1471-8. PubMed ID: 22336942
[TBL] [Abstract][Full Text] [Related]
16. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
[TBL] [Abstract][Full Text] [Related]
17. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
Cattelani S; Defferrari R; Marsilio S; Bussolari R; Candini O; Corradini F; Ferrari-Amorotti G; Guerzoni C; Pecorari L; Menin C; Bertorelle R; Altavista P; McDowell HP; Boldrini R; Dominici C; Tonini GP; Raschellà G; Calabretta B
Clin Cancer Res; 2008 Jun; 14(11):3248-53. PubMed ID: 18519749
[TBL] [Abstract][Full Text] [Related]
18. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer.
Almquist LM; Karagas MR; Christensen BC; Welsh MM; Perry AE; Storm CA; Nelson HH
Carcinogenesis; 2011 Mar; 32(3):327-30. PubMed ID: 21123835
[TBL] [Abstract][Full Text] [Related]
19. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
[TBL] [Abstract][Full Text] [Related]
20. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
